Seek Returns

RGEN vs. RVMD: Repligen vs. Revolution Medicines Stock Comparison

How do Repligen (RGEN) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Repligen (RGEN) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RGEN is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Repligen (RGEN) has more than two decades of public-market history since April 29, 1986, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Company profile comparison for Repligen (RGEN) and Revolution Medicines (RVMD)
Profile ItemRGENRVMD
NameRepligen CorporationRevolution Medicines, Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization11.09 billion USD41.59 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateApril 29, 1986February 13, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

RGEN
RVMD
GSPC
Loading price history…
Repligen (RGEN) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Repligen (RGEN) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Repligen (RGEN) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
Total Return (1Y)23.28%224.80%
Total Return (3Y, Annualized)6.20%114.71%
Total Return (5Y, Annualized)-8.41%43.47%

Risk Profile

Drawdown History

RGEN
RVMD
GSPC
Loading price history…
Repligen (RGEN) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Repligen (RGEN) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
Volatility (1Y, Annualized)46.73%68.29%
Beta (5Y)1.111.42
Max Drawdown (5Y)-64.67%-55.71%
Avg. Volume (3M)1.18M2.06M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RGEN and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
Sharpe Ratio (1Y)0.413.23
Sortino Ratio (1Y)0.606.92

Profitability

ROE (TTM)

Both Repligen (RGEN) at -0.57% and Revolution Medicines (RVMD) at -93.56% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
RVMD
-93.56%
Min
-167.77%
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Revolution Medicines (RVMD) reports 0.00%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
RVMD
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Repligen (RGEN) reports 6.19%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
RVMD
-188.88%
Min
-207.40%
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
ROE (TTM)-0.57%-93.56%
ROA (TTM)1.40%-32.13%
Net Margin (TTM)-1.47%0.00%
Operating Margin (TTM)6.19%-188.88%
Gross Margin (TTM)53.77%0.00%

Growth

Revenue Growth

Only one side can be read here: Repligen (RGEN) reports revenue growth of 16.36%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Repligen (RGEN) nor Revolution Medicines (RVMD) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
Revenue Growth (YoY)16.36%--
Revenue Growth (3Y CAGR)-2.70%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)-35.73%--

Financial Strength

Current Ratio (MRQ)

Both Repligen (RGEN) at 9.88 and Revolution Medicines (RVMD) at 8.36 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max
25.13
Q3
12.13
RVMD
8.36
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Repligen (RGEN) at 0.33 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max
1.42
Q3
0.65
RVMD
0.50
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
Current Ratio (MRQ)9.888.36
Debt / Equity (MRQ)0.330.50
Net Debt / EBITDA-1.19--

Dividends

Dividend Yield (TTM)

Neither Repligen (RGEN) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Repligen (RGEN) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Repligen (RGEN) nor Revolution Medicines (RVMD) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RVMD
--
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Repligen (RGEN) at 13.77 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD
210.51
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD
17.31
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Repligen (RGEN) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Repligen (RGEN) and Revolution Medicines (RVMD)
MetricRGENRVMD
P/E Ratio (TTM)----
P/S Ratio (TTM)13.77210.51
P/B Ratio (MRQ)4.7017.31
Free Cash Flow Yield (TTM)1.01%-2.13%